Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

2.3K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.3K
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

1.3K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.3K
Dementia01:30

Dementia

633
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
633
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

1.9K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.9K
Neural Regulation01:37

Neural Regulation

43.9K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
43.9K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

1.1K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Diffusion-Informed Joint Segmentation Enhances Detection of Thalamic Atrophy in Parkinson's Disease.

Brain topography·2026
Same author

Drug Development.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2025
Same author

A Comprehensive Overview of the Clinical, Electrophysiological, and Neuroimaging Features of BPAN: Insights From a New Case Series.

Annals of clinical and translational neurology·2025
Same author

Unravelling the plasma proteome: Pioneering biomarkers for differential dementia diagnosis.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2025
Same author

The Comparison of Functional Connectivity in Parkinson's Disease Patients with and without Parkin Gene Mutations.

Noro psikiyatri arsivi·2025
Same author

Investigation of symptom-specific functional connectivity patterns in Parkinson's disease.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·2025

Related Experiment Video

Updated: Mar 8, 2026

Characterizing the Relationship Between Eye Movement Parameters and Cognitive Functions in Non-demented Parkinson's Disease Patients with Eye Tracking
07:26

Characterizing the Relationship Between Eye Movement Parameters and Cognitive Functions in Non-demented Parkinson's Disease Patients with Eye Tracking

Published on: September 26, 2019

8.4K

Dementia in Parkinson's disease.

Hasmet A Hanagasi1, Zeynep Tufekcioglu1, Murat Emre1

  • 1Istanbul University, Istanbul Faculty of Medicine, Department of Neurology, Behavioral Neurology and Movement Disorders Unit, Istanbul, Turkey.

Journal of the Neurological Sciences
|January 16, 2017
PubMed
Summary

Dementia affects nearly 30% of Parkinson's disease patients, impacting cognition and behavior. Cholinesterase inhibitors offer modest benefits for these symptoms.

Keywords:
Cholinesterase inhibitorsDementiaDementia with Lewy BodiesParkinson's disease

More Related Videos

Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease
10:28

Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease

Published on: July 24, 2019

16.4K
Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease
05:51

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Published on: October 14, 2021

4.6K

Related Experiment Videos

Last Updated: Mar 8, 2026

Characterizing the Relationship Between Eye Movement Parameters and Cognitive Functions in Non-demented Parkinson's Disease Patients with Eye Tracking
07:26

Characterizing the Relationship Between Eye Movement Parameters and Cognitive Functions in Non-demented Parkinson's Disease Patients with Eye Tracking

Published on: September 26, 2019

8.4K
Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease
10:28

Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease

Published on: July 24, 2019

16.4K
Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease
05:51

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Published on: October 14, 2021

4.6K

Area of Science:

  • Neurology
  • Neuroscience
  • Geriatrics

Background:

  • Parkinson's disease (PD) frequently co-occurs with dementia, affecting up to 30% of patients.
  • Cognitive impairment in PD dementia includes executive, visuospatial, attention, and memory deficits.
  • Behavioral symptoms like apathy and hallucinations are common in PD dementia.

Purpose of the Study:

  • To review the characteristics of dementia in Parkinson's disease.
  • To explore the underlying pathology and biochemical deficits.
  • To evaluate the efficacy of cholinesterase inhibitors in treating PD dementia.

Main Methods:

  • Review of existing literature on Parkinson's disease dementia.
  • Analysis of cognitive and behavioral profiles.
  • Examination of pathological findings, including Lewy body pathology and cholinergic deficits.
  • Assessment of placebo-controlled randomized trials of cholinesterase inhibitors.

Main Results:

  • Predominant cognitive deficits involve executive functions, visuospatial abilities, attention, and memory.
  • Common behavioral symptoms include apathy, visual hallucinations, and delusions.
  • Lewy body pathology and cholinergic deficits are key pathological features.
  • Cholinesterase inhibitors showed modest but significant improvements in cognition, behavior, and global function.

Conclusions:

  • Dementia is a significant complication of Parkinson's disease with a distinct cognitive and behavioral profile.
  • Cholinergic deficits and Lewy body pathology are central to PD dementia.
  • Cholinesterase inhibitors represent a viable therapeutic option for managing dementia symptoms in Parkinson's disease.